Comparison · NCT00886691-sae
Everolimus (RAD001) Plus Bevacizumab vs Placebo Plus Bevacizumab: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Everolimus (RAD001) Plus Bevacizumab vs Placebo Plus Bevacizumab: serious adverse events. Trial comparisons, record NCT00886691-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00886691-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.467 | 0.358 | 0.578 | wilson | |
| Risk in group 2 | 0.32 | 0.225 | 0.432 | wilson | |
| Risk difference, group 1 minus group 2 | 0.147 | -0.00936 | 0.293 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.46 | 0.969 | 2.2 | log | |
| Odds ratio, group 1 over group 2 | 1.86 | 0.957 | 3.61 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Everolimus (RAD001) Plus Bevacizumab than on Placebo Plus Bevacizumab | 6.82 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Everolimus (RAD001) Plus Bevacizumab | EVEROLIMUS (RAD001) 10mg orally daily plus Bevacizumab IV at 10 mg/kg Day 1 and Day 15 (one cycle = 4 weeks) | 35 | 75 | EG000 |
| Group 2 | Placebo Plus Bevacizumab | ORAL PLACEBO daily plus Bevacizumab IV at 10 mg/kg Day 1 and Day 15 (one cycle = 4 weeks) | 24 | 75 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Study Treatment and up to 30 days after stopping study treatment, up to approximately 4 years and 6 months.
Source ClinicalTrials.gov
Trial
- Title
- Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- NCT number
- NCT00886691
- Phases
- PHASE2
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Placebo
- Lead sponsor
- GOG Foundation
- Results first posted
- 2018-07-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00886691?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00886691-sae